Celgene’s Revlimid is slowly gaining world wide acceptance as a standard of care for relapsed multiple myleloma patients. It was announced yesterday Japan has officially approved Revlimid’s use:
Read all about it on Business Wire.com. My question: Why is it taking so long to get American approval for the use of Revlimid for newly diagnosed multiple myeloma patients? Myeloma docs have been using it “off label” in newly diagnosed patients for four years.
Hope it doesn’t take this long to get the next best, new and improved thalidomide based drug, pomalidomide approved!
Feel good and keep smiling! Pat